Information  X 
Enter a valid email address

Verona Pharma gets green light for COVID treatment trial

By BFN News | 09:31 AM | Thursday 29 October, 2020

Biopharmaceuticals company Verona Pharma reported an operating loss of $46.2 million for the first nine months of 2020 as it began work on a potential treatment for COVID-19. This compared to a $42.7 million loss in the same period last year. However, the company raised $200 million from a private placement, bringing its net cash position to $202 million. In July, Verona received a notice to proceed from the US Food and Drug Administration for a trial of the company's pMDI ensifentrine drug for the treatment of patients hospitalised with COVID-19. The study began in September. Verona has also commenced trials of the same drug for the treatment of patients with chronic obstructive pulmonary disease. At 9:31am: (LON:VRP) Verona Pharma PLC share price was +3p at 55p Story provided by

a d v e r t i s e m e n t